Medicus Pharma completed acquisition of UK-based Antev Limited, gaining full rights to Teverelix, a GnRH antagonist targeting prostate cancer and acute urinary retention. Valued at an estimated $6 billion market opportunity, Teverelix aims to address unmet needs in prostate cancer treatment with a novel mechanism affecting hormonal regulation. The deal includes contingent payments linked to successful FDA regulatory milestones, aligning with Medicus' strategic focus on disruptive therapies for underserved indications.